SCHEDULE: CVI Investments Discloses 4.9% Stake in Plus Therapeutics

CVI Investments, Inc. and Heights Capital Management, Inc. have reported beneficial ownership of approximately 4.9% of Plus Therapeutics, Inc. common stock, primarily through warrants.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. have filed a Schedule 13G, indicating their beneficial ownership of 9,009,978 shares of Plus Therapeutics, Inc. common stock.
• This ownership represents approximately 4.9% of the class of securities outstanding as of March 18, 2026.
• The reported shares are primarily issuable upon the exercise of warrants, with a restriction that prevents exercise if beneficial ownership would exceed 4.99%.
• Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc., and may exercise voting and dispositive power over these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports an existing investment structure and does not contain new strategic information or performance data.

Positives

• The filing indicates a significant investment by CVI Investments and Heights Capital Management, potentially signaling confidence in Plus Therapeutics' future prospects.
• The reporting entities are established investment firms, suggesting a strategic and informed investment approach.

Negatives

• The ownership stake is capped at 4.99% due to warrant exercisability limitations, preventing a controlling interest through this mechanism.
• The filing does not provide details on the specific warrants or their terms, leaving room for interpretation regarding their value and potential impact.

Risks

• The reliance on warrants for ownership means the actual number of shares held could fluctuate based on warrant terms and market conditions.
• The 4.99% ownership cap limits the reporting persons' ability to influence control of the company through this specific holding.

Future Outlook

The filing does not contain forward-looking statements or specific future guidance from the reporting persons regarding their investment strategy or intentions with Plus Therapeutics.

Management Comments

• Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.
• Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investments by institutional investors. The 4.9% stake, capped by warrant terms, suggests CVI Investments and Heights Capital Management are significant but not controlling shareholders in the biotechnology sector, where such stakes are common for specialized investment firms.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's passive stake, which can provide a degree of stability but does not indicate active support or opposition to management.
• Management: The reporting persons' passive approach suggests they are unlikely to seek immediate changes in company strategy or governance, barring significant underperformance.

Next Steps

• Monitor future filings from CVI Investments, Inc. and Heights Capital Management, Inc. for any changes in their beneficial ownership of Plus Therapeutics, Inc.
• Observe Plus Therapeutics, Inc.'s corporate actions and financial performance for potential impacts related to significant institutional holdings.

Key Dates

Keywords

Plus Therapeutics, Schedule 13G, CVI Investments, Heights Capital Management, Beneficial Ownership, Warrants, SEC Filing, Common Stock, Investment Management